慢性皮肤黏膜念珠菌病1例

报道l例慢性皮肤黏膜念珠菌病.患者女,16岁.1岁开始发病,持续存在口腔、皮肤、甲板损害,真菌镜检阳性,真菌培养为白念珠菌,皮损组织病理为感染肉芽肿改变,在角质层中可见大量真菌菌丝,内分泌功能和免疫学检查未见明显异常.口服伊曲康唑治疗有效.     

深在型皮肤念珠菌病1例报告

深在型皮肤念珠菌病一般包括念珠菌肉芽肿（Candidal granuloma）和慢性皮肤黏膜念珠菌病两种。前者临床表现为增生、结节、溃疡或肉芽肿形成。国内1964年张永圣[1]等报道1例后,陆续有病例报道。该病有两种类型：Houser-Rothman型和Busse-Buschke型。Houser-Rothman型也被认为属于慢性皮肤黏膜念珠菌病的一种较严重表现[2]。本文报告1例面部的深在型皮肤念珠菌病。     

不同制剂的伊曲康唑治疗口咽念珠菌病的疗效观察

伊曲康唑(itraconazole)为三唑类广谱抗真菌药物.胶囊制剂必须与食物同服才能达到较好的生物利用度,而口服溶液制剂则通过羟丙基-β-环糊精与伊曲康唑交联,使脂溶性的伊曲康唑能溶于水,且口服吸收不受食物影响,空腹服用较餐后服用的生物利用度更高.本文将评价伊曲康唑口服液治疗口咽念珠菌病的疗效和安全性,对照药品为其胶囊制剂.……     

五环三萜类柴胡皂苷单体对白念珠菌伊曲康唑耐药株活性研究

目的 从柴胡中提取具有抗真菌活性的五环三萜类单体Bp3,研究该单体对伊曲康唑耐药白念珠菌菌株的作用及其与伊曲康唑的相互作用.方法 参照CLSI标准,采用棋盘微量稀释法,测定单用Bp3、伊曲康唑及两者联合使用时对20株伊曲康唑耐药白念珠菌菌株的MIC,计算部分抑菌浓度指数(FIC),判定两药相互作用.结果 单独用药时Bp3及伊曲康唑对伊曲康唑耐药白念珠菌菌株MIC的几何均数值(GM值)分别为1.941 μg/mL和1.008 μg/mL.联合用药时Bp3和伊曲康唑的GM值分别降低为1.189 μg/mL和0.346 μg/mL.2种药物单用和联合使用时MIC值差异均有统计学意义(P＜0.05),联用时在20株耐药株均表现为协同或相加作用.结论 五环三萜类单体Bp3对白念珠菌伊曲康唑耐药株有一定的抑制作用,且与伊曲康唑有协同或相加作用.     

伊曲康唑治疗复发性外阴阴道念珠菌病38例临床观察

目的了解国产伊曲康唑（商品名“美扶”）治疗复发性外阴阴道念珠菌病的疗效。方法收集38例复发性外阴阴道念珠菌病为治疗组,口服伊曲康唑200mg,1次／d,连续7d,以后每次月经第1天口服伊曲康唑200mg,1次／d,连续6个月经周期停药,而对照组20例则单子硝酸咪康唑栓200mg阴道外用,方法同前。两组完成冲击治疗后1周、3个月、6个月评价疗效。结果1周后治疗组总有效率为92．1％,对照组为90％,两组相比无统计学差异。3个月、6个月后治疗组的复发率分别为3．2％、6．7％,对照组为28．6％、38．5％,两组相比有统计学意义。结论伊曲康唑短程冲击治疗加长期间断给药对复发性外阴阴道念珠菌病的治疗和预防复发效果满意。     

婴儿头皮念珠菌病1例

报告菌痂型婴儿头皮念珠菌病1例。患儿头皮出现脓痂16个月。病原菌经真菌直接镜检、真菌培养、芽管试验和科玛嘉念珠菌显色培养基鉴定为白念珠菌。经溶痂和外涂1％咪康唑软膏治疗1周后痊愈。     

伊曲康唑联合硝酸咪康唑栓治疗外阴阴道念珠菌病

目的观察伊曲康唑联合硝酸咪康唑栓治疗外阴阴道念珠菌病的临床疗效。方法选择外阴阴道念珠菌病患者74例,给予联合疗法治疗。结果74例患者中痊愈29例,显效37例,有效5例,无效3例,总有效率89.19％。结论联合疗法治疗外阴阴道念珠菌病治愈率高,复发率低,临床应用效果好。     

不同剂量伊曲康唑口服联合外用抗真菌药物治疗足癣的疗效观察

目的比较伊曲康唑200mg／d与400ne／d口服联合外用复方酮康唑乳膏治疗足癣的疗效。方法36例非角化型足癣患者随机分为2组,分别采用不同剂量伊曲康唑口服联合外用复方酮康唑乳膏治疗1周,比较停药2周时两组患者的治疗有效率和真菌清除率。结果200mg组治疗有效率为83．3％（15／18）,痊愈率为55．6％（10／18）,真菌清除率为66．7％（12／18）;400mg组治疗有效率为88．9％（16／18）,痊愈率为55．6％（10／18）,真菌清除率为77．8％（14／18）;统计学分析两组之间差异无显著性。结论伊曲康唑200mg／d口服即可有效治疗非角化型足癣,增加伊曲康唑口服剂量至400mg/d并不能提高治疗效果。     

伊曲康唑胶囊治疗复发性外阴阴道念珠菌病866例疗效观察

目的探讨复发性外阴阴道念珠菌病的治疗效果。方法对866例患者进行伊曲康唑胶囊首次治疗及维持治疗,观察效果。结果首次治疗后临床治愈率56.70%,好转率43.40%,维持治疗后治愈96.70%,好转率3.30%,真菌学治愈率100%。结论伊曲康唑治疗复发性外阴阴道念珠菌病,首次治疗加维持治疗疗效高,使用方便,不良反应少。     

硝酸舍他康唑乳膏治疗儿童皮肤念珠菌病50例

目的 观察硝酸舍他康唑乳膏治疗儿童皮肤念珠菌病的疗效和安全性.方法 将就诊的100例皮肤念珠菌病患儿分为两组,治疗组50例,外搽硝酸舍他康唑乳膏2次/d,对照组50例,外搽硝酸咪康唑软膏2次/d,疗程7～14d.观察其临床疗效和不良反应.结果 治疗组临床痊愈率92.00％,对照组64.00％,两组比较差异有统计学意义(P＜O.01).与对照组比较,治疗组起效更快、皮疹消失时间更短(P＜0.01).不良反应少而轻.结论 硝酸舍他康唑乳膏治疗儿童皮肤念珠菌病起效快,安全有效,具有较高的临床应用价值.     

PCR法评价伊曲康唑注射液治疗播散性白念珠菌病兔模型疗效

目的通过静脉内接种的方法,构建播散性白念珠菌感染的兔模型,并用PCR评价伊曲康唑注射液治疗播散性念珠菌病的疗效。方法在接种后24h,用伊曲康唑注射液5rag／kg对兔模型进行治疗,1次／d,共14d。在不同的时间段取兔模型的静脉血,进行血培养和真菌通用引物以及白念珠菌特异性引物的PCR检测,监测伊曲康唑注射液治疗播散性白念珠菌感染的疗效。结果在接种白念珠菌后1h、6h,外周血中用PCR方法就能检测到白念珠菌,且能持续到8—10d;实验兔外周血血培养1h后阳性,持续到18h。实验结束后解剖实验兔,治疗组较对照组内脏器官的组织培养阳性率及菌落数低。结论PCR是一种快速和敏感的检测播散性念珠菌病的方法,伊曲康唑注射液治疗播散性白念珠菌病有效,但是真菌的清除率特别是肾脏组织的真菌清除率并不理想,治疗结束7d后,组织匀浆真菌培养仍然阳性。     

Transfer factor in chronic mucocutaneous candidiasis

Fifteen patients suffering from chronic mucocutaneous candidiasis were treated with an in vitro produced TF specific for Candida albicans antigens and/or with TF extracted from pooled buffy coats of blood donors. CMI of the patients was assessed using the LMT and the LST in presence of candidine. The aim of the study was the clinical evaluation of TF treatment and the incidence of positive tests before, during, and after therapy. Immunological data were matched using the Chi square test. 87 LMT were performed for each antigen dose and at the dilution of 1/50, 58.9% (33/56) tests were positive during non-treatment or non-specific TF treatment. On the contrary 83.9% (26/31) were positive during specific TF treatment (P<0.05). In the LST, a significant decrease of thymidine uptake in the control cultures in presence of autologous or AB serum was observed when patients were matched according to non-treatment, and both non specific (P<0.05) and specific TF treatment (P<0.01). Only during specific TF treatment was a significant increase of reactivity against the Candida antigen at the highest concentration noticed, when compared with the period of non specific treatment (P<0.01). Clinical observations were encouraging: all but one patient experienced significant improvement during treatment with specific TF. These data confirm that orally administered specific TF, extracted from induced lymphoblastoid cell-lines, increases the incidence of reactivity against Candida antigens in the LMT. LST reactivity appeared not significantly increased with respect to the periods of non treatment, but was significantly increased when it was compared to the non-specific TF treatment periods. At the same time, a clinical improvement was noticed.     

Posaconazole therapy for severe abdominal candidiasis: a case report

We report the successful treatment of a fluconazole-resistant intra-abdominal Candida infection (Candida albicans and Candida tropicalis) with posaconazole (SCH56592) in a 68-year-old woman with a recent history of intra-abdominal surgery.     

Oral candidiasis mimicking an oral squamous cell carcinoma: report of a case

doi: 10.1111/j.1741‐2358.2010.00371.x Oral candidiasis mimicking an oral squamous cell carcinoma: report of a case Oral candidiasis is a significant problem in immune‐compromised patients. The most common forms of mucosal candidiasis are oropharyngeal, oesophageal and vaginal, and more than 90% of HIV positive persons will manifest at least one episode of oropharyngeal candidiasis. Local and systemic factors such as uninterrupted daily use of a prosthesis by patients, smoking habit, as well as high glucose intake may contribute to the development of the lesion. The aim of this article is to report an uncommon case of oral candidiasis presenting an aggressive clinical behaviour in a 64‐year‐old male patient, with a significant smoking habit and a medical history of non‐controlled diabetes. The lesion affected the hard and soft palate of the right side, revealing erythematous and ulcerated areas, elevated borders and central portions resembling necrosis, mimicking the clinical features of oral squamous cell carcinoma. However, the correct diagnosis of oral candidiasis was obtained after histopathological and cytological examinations and the patient was easily treated with traditional antifungal drugs and correction of his glucose levels.     

甲真菌病患者生活质量及口服伊曲康唑间歇冲击疗法对其的影响

目的研究伊曲康唑治疗对甲真菌病患者生活质量的影响。方法221例患者应用伊曲康唑冲击治疗前后填写调查表,其中43例患者完成伊曲康唑3个疗程随访。结果全甲营养不良型甲真菌病患者生活质量下降较为明显的指标为精神、心理状态4．79±2．81,日常生活、工作能力3．33±2．11（P〈0．05）。伊曲康唑治疗后甲真菌病患者生活质量分值随疗程延长逐渐降低。结论甲真菌病患者生活质量受到影响,伊曲康唑冲击治疗能改善患者生活质量。     

以皮肤受累为首发表现的播散性念珠菌病1例并文献复习

目的：播散性念珠菌病是一种致命性真菌感染性疾病,在免疫缺陷患者中发病率逐年增多,报道1例以双下肢多发皮下结节为首发表现,伴有肺及脑受累的播散性念珠菌病,并文献复习播散性念珠菌病的皮肤受累临床表现。方法患者女,37岁。因双下肢多发皮下结节6个月余就诊。有局灶节段性肾小球硬化病史,口服强的松及他克莫司2a余。取患者皮损组织行病理学检查,皮损组织、脓液、血、痰、尿、粪、脑脊液进行真菌镜检及真菌培养,并文献检索统计播散性念珠菌病皮肤受累患者临床特点。结果皮损组织病理见假菌丝,皮损组织、脓液、痰、尿、粪标本直接涂片均见假菌丝并培养出白念珠菌,CT显示肺受累,诊断为播散性念珠菌病,予抗真菌治疗,患者皮损愈合及肺部病灶部分吸收,但因自行停药,最终出现颅内播散。结论以皮损为首发表现的播散性念珠菌病临床罕见,临床诊疗中应重视应用免疫抑制剂患者皮损的组织病理及微生物检查,及早进行诊断和治疗,防止出现系统性播散,从而降低死亡率。     

外阴阴道假丝酵母菌病的阴道清洁度观察

目的观察外阴阴道假丝酵母菌病阴道清洁度的情况。方法用湿片法进行阴道分泌物检查,随机选取1000例念珠菌阳性分泌物,对其阴道清洁度进行观察。结果1000例念珠菌阳性分泌物中,阴道清洁度Ⅳ度有606例,阴道清洁度Ⅲ度有279例,阴道清洁度Ⅱ度有82例,阴道清洁度Ⅰ度有33例。结论虽然大多数念珠菌阳性分泌物（88．5％）阴道清洁度异常（Ⅲ～Ⅳ度）,但仍然有少数念珠菌阳性分泌物（11．5％）阴道清洁度属于正常（Ⅰ～Ⅱ度）。这一结果应有助于临床妇产科医生在为患者做常规妇检、在外观性状上对阴道分泌物作判断时采取更加谨慎的态度。     

Urinary tract candidiasis: report of a case with bilateral ureteral obstruction

A brief review of the literature on urinary tract candidiasis is presented. The presence of Candida albicans in the urine is rather uncommon and most patients have candiduria without any apparent disease. Among the others, three different clinical types of infection are recognized: (1) pyelonephritis, (2) lower urinary tract infection and (3) ureteral obstruction. Of this last type only seven cases were found in the literature; four of the patients died. We add one case in which the patient did very well after the obstruction of the ureters was relieved by means of ureteral catheters and a large urinary output was maintained for several days.